Literature DB >> 10846359

[Experimental study of calcification of the xenopericardia].

H Masumoto1, T Watanabe, Y Sakai, Y Ueda.   

Abstract

UNLABELLED: We studied the calcification of four kinds of xenopericardium used in cardiac surgery. Group 1: bovine Pericardium (Tissueguard. Biovascular, inc), Group 2: bovine pericardium (No-React. Shelhigh, inc), Group 3: porcine pericardium (Rigg. Polystan, inc), Group 4: equine pericardium (Xenomedica. Baxter-Edwards, inc). Each pericardium was implanted in abdominal subcutaneous pouches of rats. The mean calcium content of each Group after eight weeks of subcutaneous implantation were 0.67 +/- 0.15 mg/g, 0.51 +/- 0.15 mg/g, 161 +/- 18 mg/g and 173 +/- 18 mg/g in Group 1, Group 2, Group 3 and Group 4, respectively. There was no significant difference between Group 1 and 2, or between Group 3 and 4. On the other hand, there were significant differences between Group 1, 2 and Group 3, 4 (p < 0.001). The deposition of calcium and inflammatory changes were markedly observed microscopically in Group 3 and 4, but in Group 1 and 2, they were only slightly observed.
CONCLUSION: Two kinds of bovine pericardium are superior to both porcine and equine pericardium in the point of less calcium deposition and inflammatory cellular response after implantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846359

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  2 in total

1.  Tissue-engineered fibrin-based heart valve with a tubular leaflet design.

Authors:  Miriam Weber; Eriona Heta; Ricardo Moreira; Valentine N Gesche; Thomas Schermer; Julia Frese; Stefan Jockenhoevel; Petra Mela
Journal:  Tissue Eng Part C Methods       Date:  2013-10-19       Impact factor: 3.056

2.  Effusive--constrictive epicarditis that developed more than 5 years after ventricular septal defect closure: two cases relieved by epicardiectomy.

Authors:  N Okamoto; H Shiraishi; H Konishi; M Y Momoi
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.